Patent 11013729

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (5)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

2015-04-16 · reel 033005/0130 · Assignment
Towa Pharmaceutical Europe SL LABORATORIOS DEL DR. ESTEVE S.A.
Correspondent: GANDHI, ANILKUMAR S., PILGAONKAR, PRATIBHA S., RUSTOMJEE, MAHARUKH T.
Transfer of assignors' interest
2018-12-17 · reel 045350/0961 · Change of Name
LABORATORIOS DEL DR. ESTEVE S.A.ESTEVE PHARMACEUTICALS, S.A.
Corporate name change
2019-12-19 · reel 049386/0203 · Change of Name
ESTEVE PHARMACEUTICALS, S.A.DOSE INNOVA, S.L.
Corporate name change
2020-12-09 · reel 053046/0993 · Change of Name
DOSE INNOVA, S.L. UNIPERSONAL TOWA PHARMACEUTICAL EUROPE, S.L. UNIPERSONAL
Corporate name change
2022-02-10 · reel 057049/0989 · Assignment
TOWA PHARMACEUTICAL EUROPE, S.L. UNIPERSONAL BRECKENRIDGE PHARMACEUTICAL, INC.
Transfer of assignors' interest

Assignment history

✓ Generated

Inventors

Pratibha S. Pilgaonkar (Employer: Towa Pharmaceutical Europe SL at time of filing)
Maharukh T. Rustomjee (Employer: Towa Pharmaceutical Europe SL at time of filing)
Anilkumar S. Gandhi (Employer: Towa Pharmaceutical Europe SL at time of filing)

Original assignee

The original assignee on the issued patent, US11013729B2, was Towa Pharmaceutical Europe SL [cite: The "Original Assignee" field on Google Patents lists "Towa Pharmaceutical Europe SL".]. It is unclear from the provided information whether Towa Pharmaceutical Europe SL shipped a product embodying the claims of this specific patent. Their primary line of business appears to be pharmaceuticals. The current status of Towa Pharmaceutical Europe SL as an operating company or otherwise is not explicitly stated in the provided text, but the patent was subsequently reassigned from them multiple times before its eventual assignment to Breckenridge Pharmaceutical Inc. [cite: The Google Patents "Legal Events" section details several reassignments from Towa Pharmaceutical Europe SL to other entities, and finally to Breckenridge Pharmaceutical, Inc.].

Assignment timeline

2015-04-16 (executed) / recorded 2015-04-16 — Reel 033005/0130
- Conveyance: Assignment
- Assignor: Towa Pharmaceutical Europe SL
- Assignee: LABORATORIOS DEL DR. ESTEVE S.A.
- Correspondent: GANDHI, ANILKUMAR S., PILGAONKAR, PRATIBHA S., RUSTOMJEE, MAHARUKH T. (Assignors in this case, not the correspondent attorney)
- Context: Transfer of assignors' interest.
2018-12-17 (executed) / recorded 2018-12-17 — Reel 045350/0961
- Conveyance: Change of Name
- Assignor: LABORATORIOS DEL DR. ESTEVE S.A.
- Assignee: ESTEVE PHARMACEUTICALS, S.A.
- Correspondent: Not specified in the provided text
- Context: Corporate name change.
2019-12-19 (executed) / recorded 2019-12-19 — Reel 049386/0203
- Conveyance: Change of Name
- Assignor: ESTEVE PHARMACEUTICALS, S.A.
- Assignee: DOSE INNOVA, S.L.
- Correspondent: Not specified in the provided text
- Context: Corporate name change.
2020-12-09 (executed) / recorded 2020-12-09 — Reel 053046/0993
- Conveyance: Change of Name
- Assignor: DOSE INNOVA, S.L. UNIPERSONAL
- Assignee: TOWA PHARMACEUTICAL EUROPE, S.L. UNIPERSONAL
- Correspondent: Not specified in the provided text
- Context: Corporate name change.
2022-02-10 (executed) / recorded 2022-02-10 — Reel 057049/0989
- Conveyance: Assignment
- Assignor: TOWA PHARMACEUTICAL EUROPE S.L. UNIPERSONAL
- Assignee: BRECKENRIDGE PHARMACEUTICAL, INC.
- Correspondent: NOT PROVIDED
- Context: Transfer of assignors' interest.

Timeline diagram

timeline
    title Ownership of US 11013729
    2013 : Application filed by Towa Pharmaceutical Europe SL
    2015 : Assigned to LABORATORIOS DEL DR. ESTEVE S.A.
    2018 : Name changed to ESTEVE PHARMACEUTICALS, S.A.
    2019 : Name changed to DOSE INNOVA, S.L.
    2020 : Name changed to TOWA PHARMACEUTICAL EUROPE, S.L. UNIPERSONAL
    2021 : Patent granted
    2022 : Assigned to BRECKENRIDGE PHARMACEUTICAL, INC.
    2024 : IPR2025-01107 filed
         : US case filed in Delaware District Court

NPE / troll-pattern signals

Shell-entity transfer — unclear. While several assignees appear to be entities ending in "S.A." or "S.L. UNIPERSONAL", which could be shell entities, there is no explicit evidence within the provided text (such as registered-agent addresses or explicit statements of their business model) to confirm they are licensing-only LLCs or do not ship products. The sequence of reassignments, particularly the multiple name changes, could potentially mask a shell transfer, but without further information, it remains unclear.
Known asserter in the chain — not present. Breckenridge Pharmaceutical Inc. is the current assignee, and they are generally considered an operating pharmaceutical company. No other entities in the chain are identified as known NPEs in the provided information.
Repeat correspondent across the chain — not present. The provided assignment records for US11013729 on Google Patents do not consistently list a correspondent attorney or firm. For the initial assignment in 2015, the assignors themselves are listed as the "Correspondent," which is an unusual pattern. For subsequent reassignments and name changes, the correspondent information is not provided in the snippets. Therefore, there is no evidence of a repeat correspondent across the chain.
Cascading transfers — unclear. There are multiple consecutive reassignments and name changes within a relatively short period (from 2015 to 2022, with several changes occurring annually). While these are largely described as "change of name" events, it does show a degree of organizational fluidity or restructuring. However, without correspondent information, shared principals, or addresses, it's difficult to definitively confirm this as a cascading transfer pattern indicative of an NPE.
Pre-litigation transfer — not present. The earliest litigation event identified is the Delaware District Court case (1:24-cv-00571) filed in 2024, or the IPR in August 2024. The last assignment to Breckenridge Pharmaceutical Inc. was in February 2022 [cite: The Google Patents "Legal Events" section shows "2022-02-10 Assigned to BRECKENRIDGE PHARMACEUTICAL, INC."]. This is more than six months prior to the identified litigation, so it does not fit the pattern of a pre-litigation transfer.
Bankruptcy fire-sale — not present. There is no information provided indicating any of the assignors or assignees in the chain underwent bankruptcy proceedings.
Privateering — not present. No evidence in the provided data suggests an operating company transferred the patent to an NPE to assert on their behalf.
Defensive aggregator (anti-NPE) — not present. The current assignee, Breckenridge Pharmaceutical Inc., is an operating company, not a defensive aggregator.

Verdict

Insufficient data. While there are several reassignment events and name changes, there is insufficient information regarding the nature of these entities (e.g., whether they ship products, their business models, or detailed correspondent information) to confidently label this as an NPE pattern. The current assignee, Breckenridge Pharmaceutical Inc., appears to be an operating company.

USPTO Assignment Center search for US11013729

Generated 5/17/2026, 12:48:26 AM